About: Peter Horak

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Peter Horak Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher ORCID ID = 0000-0003-4536-9306

Attributes	Values
rdf:type	Item
description	forskare (sv) ikertzailea (eu) araştırmacı (tr) эрдэмтэн (mn) 研究者 (zh) onderzoeker (nl) researcher ORCID ID = 0000-0003-4536-9306 (en)
rdfs:label	Peter Horak (en) Peter Horak (es) Peter Horak (nl) Peter Horak (ast)
skos:prefLabel	Peter Horak (en) Peter Horak (es) Peter Horak (nl) Peter Horak (ast)
name	Peter Horak (en) Peter Horak (es) Peter Horak (nl) Peter Horak (ast)
Scopus author ID	wds:Q58408197-2C266131-26EF-4224-A443-B9D991C0797A
Scopus author ID	10243987000
given name	wds:Q58408197-A09FFC66-4792-499D-B05E-4FC66DE5FCFA
given name	Peter
instance of	wds:Q58408197-5808D81B-97BF-4C54-88BB-B95707B7350F
instance of	Homo sapiens
occupation	wds:Q58408197-3B099CEF-E73A-4813-95A2-E2780BC98F40
employer	wds:Q58408197-092A0F35-9054-46CF-824E-C3EBABEB8093 wds:Q58408197-1FC64C73-FD29-4F65-BFEA-25196B29DC03 wds:Q58408197-8232BEB6-5073-457A-ADD4-5F048A9DAEC9 wds:Q58408197-8D5A5041-8A70-415E-BB07-A393FBA3BA02 wds:Q58408197-D8798F75-BED8-4C1A-B0D3-43127C3C7C3A wds:Q58408197-E66D4CCB-C96F-4875-9B5B-01AD922CAABC
sex or gender	wds:Q58408197-49A01A57-6882-4F38-B6E8-89A34CE01635
VIAF ID	wds:Q58408197-AC4255BB-B5C5-4316-9D79-693DECE67A04
GND ID	wds:Q58408197-99184097-73e6-40cc-af60-44dec2f1e00a
WorldCat Identities ID (superseded)	wds:Q58408197-A4B2BB3D-2550-4C73-9AE8-47865EADDE19
VIAF ID	http://viaf.org/viaf/3280152451238406650000
GND ID	https://d-nb.info/gnd/1156426111
occupation	researcher
employer	Medical University of Vienna German Cancer Research Center University Hospital Heidelberg Harvard Medical School Sozialmedizinisches Zentrum Ost – Donauspital
sex or gender	male
VIAF ID	3280152451238406650000
GND ID	1156426111
WorldCat Identities ID (superseded)	viaf-3280152451238406650000
ORCID iD	wds:Q58408197-28899FD9-B326-4A7A-AD46-EEF7F0E7FDFC
ORCID iD	https://orcid.org/0000-0003-4536-9306
ORCID iD	0000-0003-4536-9306
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q58408197
is author of	Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer. Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells. Methylation status of TUSC3 is a prognostic factor in ovarian cancer HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer Precision oncology based on omics data: The NCT Heidelberg experience Community-driven development of a modified progression-free survival ratio for precision oncology Genomics of Immunotherapy-Associated Hyperprogressors-Letter. NRG1 Fusions in KRAS Wild-type Pancreatic Cancer. Defective homologous recombination DNA repair as therapeutic target in advanced chordoma Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells. hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor-κB. Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field TUSC3: functional duality of a cancer gene. Finding Options Beyond Standard of Care in Oncology: A Proposal for Workflows Utilizing Knowledge Databases Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine [Personalized oncology]. Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy Successful BRAF/MEK inhibition in a patient with BRAF V600E-mutated extrapancreatic acinar cell carcinoma Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast The landscape of chromothripsis across adult cancer types Variant classification in precision oncology Sarcoma classification by DNA methylation profiling Patient expectations are better for immunotherapy than traditional chemotherapy for cancer
is author of	wds:Q35155251-3924F585-A1F9-4CFE-AC90-CD4F65730C5E wds:Q40405998-EDA71A0A-E2FC-45A9-B9BF-5F4FE0D2E26A wds:Q80350305-D147D265-2ABD-4BBB-ABE9-C8BFF7782307 wds:Q91673696-4C75375E-C033-424C-AF57-26834CAB0B11 wds:Q112820819-72142689-0915-49E5-95AE-5F590C9F362D

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software